Lipids in polycystic ovary syndrome: Role of hyperinsulinemia and effects of metformin

American Journal of Obstetrics and Gynecology

Volumn 194, Issue 5, 2006, Pages 1266-1272

  Banaszewska, Beata ^a   Duleba, Antoni J ^b   Spaczynski, Robert Z ^a   Pawelczyk, Leszek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lipids; Metformin; PCOS

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; METFORMIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; NAUSEA; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; CASE-CONTROL STUDIES; CHOLESTEROL; FEMALE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; LIPOPROTEINS, LDL; METFORMIN; POLYCYSTIC OVARY SYNDROME; TIME FACTORS; TRIGLYCERIDES;

EID: 33646076447     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2005.11.009     Document Type: Article

References (43)

1. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
2. Diamanti-Kandarakis E., Kouli C.R., Bergiele A.T., Filandra F.A., Tsianateli T.C., Spina G.G., et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84 (1999) 4006-4011
3. Asuncion M., Calvo R.M., San Millan J.L., Sancho J., Avila S., and Escobar-Morreale H.F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85 (2000) 2434-2438
4. Yen S.S., Vela P., and Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 30 (1970) 435-442
5. Chang R.J., Nakamura R.M., Judd H.L., and Kaplan S.A. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 57 (1983) 356-359
6. Burghen G.A., Givens J.R., and Kitabchi A.E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50 (1980) 113-116
7. Dunaif A., Graf M., Mandeli J., Laumas V., and Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 65 (1987) 499-507
8. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
9. Wild R.A., Painter P.C., Coulson P.B., Carruth K.B., and Ranney G.B. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 61 (1985) 946-951
10. Mahabeer S., Naidoo C., Norman R.J., Jialal I., Reddi K., and Joubert S.M. Metabolic profiles and lipoprotein lipid concentrations in non-obese and obese patients with polycystic ovarian disease. Horm Metab Res 22 (1990) 537-540
11. Holte J., Bergh T., Berne C., and Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol 41 (1994) 463-471
12. Atiomo W.U., Bates S.A., Condon J.E., Shaw S., West J.H., and Prentice A.G. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 69 (1998) 236-241
13. Conway G.S., Agrawal R., Betteridge D.J., and Jacobs H.S. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 37 (1992) 119-125
14. Guzick D.S., Talbott E.O., Sutton-Tyrrell K., Herzog H.C., Kuller L.H., and Wolfson Jr. S.K. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 174 (1996) 1224-1229
15. Dahlgren E., Johansson S., Lindsted G., Knutsson F., Oden A., Janson P., et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 57 (1992) 505-513
16. Dahlgren E., Janson P.O., Johansson S., Lapidus L., and Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand 71 (1992) 599-604
17. Anonymous. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. UK Prospective Diabetes Study Group. Diabetes Care 21 (1998) 87-92
18. Anonymous. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310 (1995) 83-88
19. Anonymous. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 854-865
20. DeFronzo R.A., Barzilai N., and Simonson D.C. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 73 (1991) 1294-1301
21. Velazquez E.M., Mendoza S., Hamer T., Sosa F., and Glueck C.J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metab Clin Experim 43 (1994) 647-654
22. Velazquez E., Acosta A., and Mendoza S.G. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 90 (1997) 392-395
23. Nestler J.E., Jakubowicz D.J., Evans W.S., and Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338 (1998) 1876-1880
24. Moghetti P., Castello R., Negri C., Tosi F., Perrone F., Caputo M., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85 (2000) 139-146
25. Santana L.F., de Sa M.F., Ferriani R.A., de Moura M.D., Foss M.C., and dos Reis R.M. Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol Endocrinol 19 (2004) 88-96
26. Rautio K., Tapanainen J.S., Ruokonen A., and Morin-Papunen L.C. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 152 (2005) 269-275
27. Cibula D., Fanta M., Vrbikova J., Stanicka S., Dvorakova K., Hill M., et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod 20 (2005) 180-184
28. Ng E.H., Wat N.M., and Ho P.C. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 16 (2001) 1625-1631
29. DeFronzo R.A., and Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333 (1995) 541-549
30. Fanghanel G., Sanchez-Reyes L., Trujillo C., Sotres D., and Espinosa-Campos J. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabetes Care 19 (1996) 1185-1189
31. Grant P.J. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 19 (1996) 64-66
32. Carlsen S.M., Rossvoll O., Bjerve K.S., and Folling I. Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. J Int Med 239 (1996) 227-233
33. Charles M.A., Eschwege E., Grandmottet P., Isnard F., Cohen J.M., Bensoussan J.L., et al. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev 16 (2000) 2-7
34. Fontbonne A., Charles M.A., Juhan-Vague I., Bard J.A., Andre P., Isnard F., et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 19 (1996) 920-926
35. Robinson A.C., Burke J., Robinson S., Johnston D.G., and Elkeles R.S. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 21 (1998) 701-705
36. Fleming R., Hopkinson Z.E., Wallace A.M., Greer I.A., and Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endorinol Metab 87 (2002) 569-574
37. Laakso M., Pyorala K., Voutilainen E., and Marniemi J. Plasma insulin and serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetic and non-diabetic subjects. Am J Epidemiol 125 (1987) 611-621
38. Abbasi F., McLaughlin T., Lamendola C., Yeni-Komshian H., Tanaka A., Wang T., et al. Fasting remnant lipoprotein cholesterol and triglyceride concentrations are elevated in nondiabetic, insulin-resistant, female volunteers. J Clin Endorinol Metab 84 (1999) 3903-3906
39. Zavaroni I., Bonora E., Pagliara M., Dall'Aglio E., Luchetti L., Buonanno G., et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 320 (1989) 702-706
40. Kolodziejczyk B., Duleba A.J., Spaczynski R.Z., and Pawelczyk L. Metformin therapy improves hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 73 (2000) 11149-11154
41. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Rev 18 (1997) 774-800
42. Robinson S., Henderson A.D., Gelding S.V., Kiddy D., Niththyananthan R., Bush A., et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol 44 (1996) 277-284
43. Psyrogiannis A.J., Alexopoulos D.K., Kyriazopoulou V.E., and Vagenakis A.G. Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in patients with coronary artery disease independent of obesity. Angiology 49 (1998) 607-612